CoreCivic CXW

NYSE CXW

$34.36 -0.69 (-1.97%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap3.40 Bn

P/E26.57

P/S1.37

Div. Yield0.00

Total Debt (Qtr)1.35 Bn

Revenue Growth (1y) (Qtr)27.27

Add ratio to table…

About

CoreCivic is a diversified government solutions company that provides corrections and detention management operates residential reentry centers and offers government real estate solutions. The company serves federal state and local government agencies with a focus on public safety and offender rehabilitation. It has been a partner to government for over forty years and is recognized as the nation's largest owner of partnership correctional detention and residential reentry…

CoreCivic generates revenue primarily by charging per diem rates for bed occupancy in its correctional detention and residential reentry facilities and by leasing owned properties to government agencies through its CoreCivic Properties segment. The company also receives income from ancillary services such as transportation electronic monitoring and case management. Its customer base consists mainly of federal state and local government entities that contract for bed capacity and related support services.

The company operates through the following segments: CoreCivic Safety CoreCivic Community and CoreCivic Properties.

CoreCivic Safety operates correctional and detention facilities that are owned or controlled via long term lease and managed by CoreCivic includes facilities owned by third parties but managed by the company and encompasses the transportation services provided by its subsidiary TransCor America LLC.
CoreCivic Community manages residential reentry centers that are owned or controlled via long term lease and managed by CoreCivic and provides electronic monitoring and case management services to government agencies.
CoreCivic Properties owns five correctional real estate properties that are held for lease to government agencies.

CoreCivic holds a leading position in the corrections and detention industry as the nation's largest owner of partnership correctional detention and residential reentry facilities and as one of the largest operators of such facilities in the United States. The company also ranks as the second largest private owner and provider of community corrections services nationwide. Its competitive advantages stem from its extensive scale long term contractual relationships with government agencies a high contract renewal rate of approximately ninety seven percent and a diversified portfolio that spans facility operations community reentry and property leasing.

The company's customers are primarily federal state and local government agencies. Federal customers include the Immigration and Customs Enforcement agency the United States Marshals Service and the Federal Bureau of Prisons. State customers represented by agencies such as the State of Tennessee the State of Montana and the State of Georgia among others. Local government entities also contract for bed capacity and reentry services.

Investment Thesis

▲ Bull case

CoreCivic, Inc. is positioned to capitalize on a structural shift toward turnkey facility acquisitions by ICE and other federal agencies, as management noted in the Q&A that the administration continues to emphasize border security and active ICE enforcement, with a clear preference for acquiring existing, operational facilities over unproven warehouse conversions. The company already has five idle facilities containing approximately 7,000 beds ready for activation, and its recent success in stabilizing operations at newly activated sites like the West Tennessee Detention Center and the Midwest Regional Reception Center demonstrates proven capability to rapidly bring capacity online. This positions CoreCivic to capture incremental demand as ICE rebuilds its detention capacity following the Q2 population dip, with management explicitly stating that the recent decline is temporary and event-specific, and that guidance assumes growth in ICE populations under existing contracts during the second half of the year. The activation of these idle facilities is already contributing to financial performance, with the Midwest Regional Reception Center expected to add $0.05–$0.06 in incremental EPS for the remainder of 2026, and the company maintains visibility into further activations as federal partners seek reliable, compliant, and humane detention solutions—core strengths consistently highlighted by management as differentiators in a fragmented market where turnkey providers are scarce.
The acquisition of Clinical Solutions Pharmacy (CSP) represents a transformative, high-margin growth platform that is underappreciated by the market, as CSP serves over 600 correctional facilities across 28 states with no single customer exceeding 15% of revenue, indicating low concentration risk and significant runway for organic and inorganic expansion. Management emphasized that CSP’s growth potential exceeds the 10% CAGR embedded in 2026 guidance, with historical growth rates likely twice that, driven by aging correctional populations and increasing medical complexity—trends that are structural, not cyclical. CSP’s centralized, highly automated operations (50% automation rate, 60,000 prescriptions/day) provide scalable efficiency, and its exclusivity to the corrections market creates a defensible niche with high switching costs. Furthermore, the acquisition creates cross-selling opportunities, as noted by Patrick Swindle, allowing CoreCivic to bundle pharmacy services with detention management to deepen relationships with state and federal partners, thereby increasing customer retention and wallet share. This diversification reduces reliance on volatile ICE population flows and adds a predictable, recurring revenue stream with margins likely superior to core detention operations, especially as CSP’s client base expands into the 22 states where it currently has no presence.
CoreCivic’s capital allocation strategy reflects a profound disconnect between intrinsic value and market pricing, as management repeatedly emphasized that the stock trades at a discount to historical multiples and to the fair value of its real estate assets, despite visible cash flow growth from facility activations and the CSP acquisition. The company has repurchased 28.1 million shares since 2022 at an average price of $15.82, with $255.8 million still available under board authorization, and leverages its strong balance sheet—$209.7 million in cash and $341 million in total liquidity—to prioritize buybacks when accretive. Crucially, David Garfinkle noted that the CSP acquisition was financed at a price generating a return on capital equal to or exceeding share repurchases, implying the market undervalues both the core business and the acquisition. With adjusted EBITDA guidance raised to $453.8–$461.8 million for 2026 (up from $437–$445 million) and AFFO projected at $250.4–$264.9 million, the company generates substantial free cash flow to support continued buybacks, debt reduction, or strategic investments. The market’s failure to recognize this cash flow generation—particularly amid the temporary ICE population dip—presents a clear arbitrage opportunity, as CoreCivic’s asset-light, high-barrier-to-entry model in a consolidating industry offers sustainable, predictable returns that are not reflected in its current valuation multiples.

CoreCivic, Inc. is positioned to capitalize on a structural shift toward turnkey facility acquisitions by ICE and other federal agencies, as management noted in the Q&A that the administration continues to emphasize border security and active ICE enforcement, with a clear preference for acquiring existing, operational facilities over unproven warehouse conversions. The company already has five idle facilities containing approximately 7,000 beds ready for activation, and its recent success in stabilizing operations at newly activated sites like the West Tennessee Detention Center and the Midwest Regional Reception Center demonstrates proven capability to rapidly bring capacity online. This positions CoreCivic to capture incremental demand as ICE rebuilds its detention capacity following the Q2 population dip, with management explicitly stating that the recent decline is temporary and event-specific, and that guidance assumes growth in ICE populations under existing contracts during the second half of the year. The activation of these idle facilities is already contributing to financial performance, with the Midwest Regional Reception Center expected to add $0.05–$0.06 in incremental EPS for the remainder of 2026, and the company maintains visibility into further activations as federal partners seek reliable, compliant, and humane detention solutions—core strengths consistently highlighted by management as differentiators in a fragmented market where turnkey providers are scarce.
The acquisition of Clinical Solutions Pharmacy (CSP) represents a transformative, high-margin growth platform that is underappreciated by the market, as CSP serves over 600 correctional facilities across 28 states with no single customer exceeding 15% of revenue, indicating low concentration risk and significant runway for organic and inorganic expansion. Management emphasized that CSP’s growth potential exceeds the 10% CAGR embedded in 2026 guidance, with historical growth rates likely twice that, driven by aging correctional populations and increasing medical complexity—trends that are structural, not cyclical. CSP’s centralized, highly automated operations (50% automation rate, 60,000 prescriptions/day) provide scalable efficiency, and its exclusivity to the corrections market creates a defensible niche with high switching costs. Furthermore, the acquisition creates cross-selling opportunities, as noted by Patrick Swindle, allowing CoreCivic to bundle pharmacy services with detention management to deepen relationships with state and federal partners, thereby increasing customer retention and wallet share. This diversification reduces reliance on volatile ICE population flows and adds a predictable, recurring revenue stream with margins likely superior to core detention operations, especially as CSP’s client base expands into the 22 states where it currently has no presence.
CoreCivic’s capital allocation strategy reflects a profound disconnect between intrinsic value and market pricing, as management repeatedly emphasized that the stock trades at a discount to historical multiples and to the fair value of its real estate assets, despite visible cash flow growth from facility activations and the CSP acquisition. The company has repurchased 28.1 million shares since 2022 at an average price of $15.82, with $255.8 million still available under board authorization, and leverages its strong balance sheet—$209.7 million in cash and $341 million in total liquidity—to prioritize buybacks when accretive. Crucially, David Garfinkle noted that the CSP acquisition was financed at a price generating a return on capital equal to or exceeding share repurchases, implying the market undervalues both the core business and the acquisition. With adjusted EBITDA guidance raised to $453.8–$461.8 million for 2026 (up from $437–$445 million) and AFFO projected at $250.4–$264.9 million, the company generates substantial free cash flow to support continued buybacks, debt reduction, or strategic investments. The market’s failure to recognize this cash flow generation—particularly amid the temporary ICE population dip—presents a clear arbitrage opportunity, as CoreCivic’s asset-light, high-barrier-to-entry model in a consolidating industry offers sustainable, predictable returns that are not reflected in its current valuation multiples.

▼ Bear case

CoreCivic, Inc. remains critically dependent on volatile ICE detention populations, which declined by roughly 3,000 individuals from the January 2026 peak through April 2026, and management’s assertion that this is temporary overlooks the structural risk posed by ICE’s active exploration of warehouse conversions and direct facility ownership—strategies explicitly mentioned by Patrick Swindle as under consideration by the agency. While management insists on a rebound in ICE populations during the second half of 2026, the guidance assumes a return to ~70,000 nationwide ICE detainees by Q3–Q4, a level that remains below the January peak of 70,800 and ignores the possibility that ICE may permanently reduce its reliance on private contractors by shifting to government-owned or warehouse-based solutions. The company’s reliance on ICE for 58% of Q1 revenue, with ICE revenue up 96.2% year-over-year driven largely by population surges, creates significant concentration risk; any sustained shift in ICE enforcement strategy—such as increased use of alternatives to detention, expanded CBP partnerships, or federal investment in publicly operated facilities—would directly undermine CoreCivic’s top-line growth trajectory, especially given that the company has no control over federal procurement timelines or agency budget allocations.
The Clinical Solutions Pharmacy (CSP) acquisition, while strategically framed as diversifying, introduces integration and execution risks that management downplayed, particularly the claim that operating synergies are “fairly limited” because CSP will remain a standalone subsidiary. This lack of integration limits near-term cost savings and raises questions about whether the $148 million purchase price (excluding transaction costs) can be justified without meaningful revenue or margin synergies. CSP’s growth narrative relies on an aging correctional population and increasing medical needs, but these trends are long-term and may not translate to near-term acceleration, especially as state and federal budgets face pressure—potentially limiting outsourcing demand for pharmacy services. Furthermore, CSP’s customer concentration, while noted as no single client exceeding 15%, still leaves it heavily reliant on the corrections sector, which is cyclical and politically sensitive; any reduction in incarceration rates or shift toward community-based alternatives could simultaneously hurt both CoreCivic’s detention business and CSP’s pharmacy sales, creating correlated downside risk rather than true diversification. Management’s admission that CSP’s growth rate is likely “twice” the 10% CAGR in guidance remains vague and unverified, with no disclosed historical growth rates or customer retention metrics to substantiate the premium valuation implied by the acquisition.
CoreCivic’s balance sheet flexibility, while presented as a strength, is increasingly constrained by rising leverage and limited avenues for meaningful accretive growth beyond share repurchases, which may not be the optimal use of capital if the stock is truly undervalued. Net debt to adjusted EBITDA stood at 2.8x as of March 31, 2026, and the $100 million incremental term loan taken to replenish the revolving credit facility after the CSP acquisition adds near-term maturity pressure, despite its 364-day term and prepayable nature. The company’s guidance excludes potential asset sales or dispositions, yet management repeatedly referenced assessing such options to enhance liquidity—a signal that internal confidence in organic growth may be waning. Furthermore, the share repurchase program, while accretive at current prices, relies on the assumption that the market will eventually recognize intrinsic value; if the discount to historical multiples persists due to ESG headwinds, reputational risks associated with private prison operations, or persistent investor aversion to the sector, buybacks may merely trap capital in a declining multiple. With no new contract announcements included in guidance and five idle facilities (7,066 beds) remaining unactivated, the company’s growth outlook hinges on uncertain federal contracting timing, leaving it exposed to prolonged periods of underutilization if ICE’s demand shift proves permanent or if state partners delay new procurements due to budgetary or political constraints.

CoreCivic, Inc. remains critically dependent on volatile ICE detention populations, which declined by roughly 3,000 individuals from the January 2026 peak through April 2026, and management’s assertion that this is temporary overlooks the structural risk posed by ICE’s active exploration of warehouse conversions and direct facility ownership—strategies explicitly mentioned by Patrick Swindle as under consideration by the agency. While management insists on a rebound in ICE populations during the second half of 2026, the guidance assumes a return to ~70,000 nationwide ICE detainees by Q3–Q4, a level that remains below the January peak of 70,800 and ignores the possibility that ICE may permanently reduce its reliance on private contractors by shifting to government-owned or warehouse-based solutions. The company’s reliance on ICE for 58% of Q1 revenue, with ICE revenue up 96.2% year-over-year driven largely by population surges, creates significant concentration risk; any sustained shift in ICE enforcement strategy—such as increased use of alternatives to detention, expanded CBP partnerships, or federal investment in publicly operated facilities—would directly undermine CoreCivic’s top-line growth trajectory, especially given that the company has no control over federal procurement timelines or agency budget allocations.
The Clinical Solutions Pharmacy (CSP) acquisition, while strategically framed as diversifying, introduces integration and execution risks that management downplayed, particularly the claim that operating synergies are “fairly limited” because CSP will remain a standalone subsidiary. This lack of integration limits near-term cost savings and raises questions about whether the $148 million purchase price (excluding transaction costs) can be justified without meaningful revenue or margin synergies. CSP’s growth narrative relies on an aging correctional population and increasing medical needs, but these trends are long-term and may not translate to near-term acceleration, especially as state and federal budgets face pressure—potentially limiting outsourcing demand for pharmacy services. Furthermore, CSP’s customer concentration, while noted as no single client exceeding 15%, still leaves it heavily reliant on the corrections sector, which is cyclical and politically sensitive; any reduction in incarceration rates or shift toward community-based alternatives could simultaneously hurt both CoreCivic’s detention business and CSP’s pharmacy sales, creating correlated downside risk rather than true diversification. Management’s admission that CSP’s growth rate is likely “twice” the 10% CAGR in guidance remains vague and unverified, with no disclosed historical growth rates or customer retention metrics to substantiate the premium valuation implied by the acquisition.
CoreCivic’s balance sheet flexibility, while presented as a strength, is increasingly constrained by rising leverage and limited avenues for meaningful accretive growth beyond share repurchases, which may not be the optimal use of capital if the stock is truly undervalued. Net debt to adjusted EBITDA stood at 2.8x as of March 31, 2026, and the $100 million incremental term loan taken to replenish the revolving credit facility after the CSP acquisition adds near-term maturity pressure, despite its 364-day term and prepayable nature. The company’s guidance excludes potential asset sales or dispositions, yet management repeatedly referenced assessing such options to enhance liquidity—a signal that internal confidence in organic growth may be waning. Furthermore, the share repurchase program, while accretive at current prices, relies on the assumption that the market will eventually recognize intrinsic value; if the discount to historical multiples persists due to ESG headwinds, reputational risks associated with private prison operations, or persistent investor aversion to the sector, buybacks may merely trap capital in a declining multiple. With no new contract announcements included in guidance and five idle facilities (7,066 beds) remaining unactivated, the company’s growth outlook hinges on uncertain federal contracting timing, leaving it exposed to prolonged periods of underutilization if ICE’s demand shift proves permanent or if state partners delay new procurements due to budgetary or political constraints.

Consolidation Items Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Facility Services

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	CTAS	Cintas Corp	primary	80.04 Bn	40.02	7.11	2.43 Bn
2	IRM	Iron Mountain Inc	primary	34.33 Bn	82.01	4.54	17.57 Bn
3	ROL	Rollins Inc	primary	16.59 Bn	31.19	4.23	0.92 Bn
4	APG	APi Group Corp	primary	16.40 Bn	-66.14	1.94	3.83 Bn
5	ARMK	Aramark	primary	14.94 Bn	38.94	0.75	6.13 Bn
6	FSV	FirstService Corp	primary	6.27 Bn	30.48	1.12	1.26 Bn
7	UNF	Unifirst Corp	primary	4.96 Bn	42.83	1.99	-
8	GEO	Geo Group Inc	primary	4.11 Bn	14.24	1.45	1.54 Bn

CoreCivic CXW

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password